2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1

PD-1/PD-L1

PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

PDF 0.7 MB

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-156151
    CYP51/PD-L1-IN-3
    		Inhibitor
    CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death.
    CYP51/PD-L1-IN-3
  • HY-P10826
    PD-1/PD-L1 inhibitory peptide C8
    		Inhibitor
    PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model.
    PD-1/PD-L1 inhibitory peptide C8
  • HY-144497
    HE-S2
    		Inhibitor
    HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity.
    HE-S2
  • HY-169190
    PD-1/PD-L1-IN-53
    		Inhibitor
    PD-1/PD-L1-IN-53 (compound B3) is an inhibitor targeting PD-1/PD-L1 and VISTA signaling pathways. PD-1/PD-L1-IN-53 can be used in anti-cancer research.
    PD-1/PD-L1-IN-53
  • HY-170793
    PD-L1/VISTA-IN-1
    		Inhibitor
    PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual-target inhibitor of PD-L1 and VISTA. PD-L1/VISTA-IN-1 can block the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), thereby reactivating T cells. PD-L1/VISTA-IN-1 has anti-tumor activity.
    PD-L1/VISTA-IN-1
  • HY-P990704
    Rilvegostomig
    		99.00%
    Rilvegostomig is an anti-PDCD1/TIGIT human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Rilvegostomig
  • HY-161605
    HBV/HDV-IN-2
    		Inhibitor
    HBV/HDV-IN-2 (Compd 143) is a HBV, HDV and PD-1/PD-L1 inhibitor, with an EC50 of 35 nM for T cell activation.
    HBV/HDV-IN-2
  • HY-P990738
    Enristomig
    Enristomig is an anti-TNFRSF9/CD274 monoclonal antibody.
    Enristomig
  • HY-P990700
    Tobemstomig
    Tobemstomig is an anti-PDCD1/LAG3 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Tobemstomig
  • HY-19991A
    (Rac)-BMS-1
    		Inhibitor
    (Rac)-BMS-1 is a racemate of BMS-1 (HY-19991A). (Rac)-BMS-1 can be used as a target protein ligand to synthesize D5B PROTAC (HY-169392).
    (Rac)-BMS-1
  • HY-161713
    PD-1/PD-L1-IN-45
    		Inhibitor
    PD-1/PD-L1-IN-45 (Compound 2) is an inhibitor for PD-1/PD-L1 Interaction with EC50 of 21.8 nM.
    PD-1/PD-L1-IN-45
  • HY-157569
    PD1-PDL1-IN 2
    PD1-PDL1-IN 2 (ZE132) is a potent and selective PD-1/PD-L1 inhibitor, which has robust anti-tumour activity in vivo. PD1-PDL1-IN 2 promotes cytotoxic T-cell tumour infiltration and induces IL-2 expression. In addition, PD1-PDL1-IN 2 elicits strong inhibitory effects on the mRNA expression of TGF-β.
    PD1-PDL1-IN 2
  • HY-169436
    Lon-TK
    		Inhibitor
    Lon-TK is a glycolysis inhibitor + linker conjugate of LTB (HY-169434). LTB is an intelligent responsive prodrug that connects Lonidamine (Lon) (HY-B0486) and a PD-L1 inhibitor (BMS-1, HY-19991) through a thioketal linker. It significantly inhibits the glycolytic metabolism of tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK shows potential for application in photodynamic-enhanced immunotherapy research.
    Lon-TK
  • HY-P99457
    Balstilimab
    		Inhibitor 99.51%
    Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1.
    Balstilimab
  • HY-163958
    PD-L1-IN-7
    		Inhibitor
    PD-L1-IN-7 (compound CB31) is an inhibitor of PD-L1, which can induce PD-L1 internalization and PD-L1 retention in cells. PD-L1-IN-7 can inhibit the interaction of PD-1/PD-L1 (IC50: 0.2 nM), change the glycosylation pattern, and promote PD-L1 degradation. PD-L1-IN-7 can also enhance T cell infiltration, amplify T cell function and the ability to kill tumor cells.
    PD-L1-IN-7
  • HY-P2564
    Human PD-L1 inhibitor III
    		Inhibitor
    Human PD-L1 inhibitor III is a human PD-L1 inhibitor.
    Human PD-L1 inhibitor III
  • HY-P990722
    Danvilostomig
    Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody.
    Danvilostomig
  • HY-P99709
    Lodapolimab
    		Inhibitor
    Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody.
    Lodapolimab
  • HY-163837
    PD-1/PD-L1-IN-48
    		Inhibitor
    PD-1/PD-L1-IN-48 (compound HD10) is a potent inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.1 nM. PD-1/PD-L1-IN-48 plays an important role in cancer research.
    PD-1/PD-L1-IN-48
  • HY-168080
    PD-1/PD-L1-IN-51
    		Inhibitor
    PD-1/PD-L1-IN-51 (Compound III-4) is a PD-1/PD-L1 inhibitor (IC50: 2.9 nM for hPD-L1). PD-1/PD-L1-IN-51 directly binds to PD-L1 to block the interaction between PD-1/PD-L1 and enhances IFN-γ release. PD-1/PD-L1-IN-51 has tumor inhibitory activity.
    PD-1/PD-L1-IN-51
Cat. No. Product Name / Synonyms Application Reactivity